Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes

Clinical Cornerstone

Volumn 8, Issue 2, 2007, Pages 10-20

  Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; CHLORPROPAMIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TELMISARTAN; TETRAHYDROLIPSTATIN; TROGLITAZONE; VALSARTAN; ANTIDIABETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE TITRATION; EDEMA; GLYCEMIC CONTROL; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER TOXICITY; LOW CALORY DIET; LOW FAT DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PREGNANCY DIABETES MELLITUS; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; DIET THERAPY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ACARBOSE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NUTRITIONAL STATUS; PREDIABETIC STATE; RISK FACTORS;

EID: 41949129819     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)60004-1     Document Type: Article

References (29)

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National diabetes statistics. Available at: http://www.diabetes.niddk.nih.gov/dm/pubs/statistics/ Accessed April 25, 2007.
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26 (2003) 917-932
3. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appears in Diabetes. 1996;45:1655]. Diabetes 44 (1995) 1249-1258
4. Icks A., Rathmann W., Haastert B., et al., for the KORA Study Group. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: Model based on the KORA Survey 2000. Diabet Med 24 (2007) 473-480
5. Jacobs-van der Bruggen M.A., Bos G., Bemelmans W.J., et al. Lifestyle interventions are cost-effective in people with different levels of diabetes risk. Results from a modeling study. Diabetes Care 30 (2007) 128-134
6. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
7. Biuso T.J., Butterworth S., and Linden A. A conceptual framework for targeting prediabetes with lifestyle, clinical, and behavioral management interventions. Disease Management 10 (2007) 6-15
8. Pan X.-R., Li G.-W., Hu Y.-H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerances. The Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
9. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
10. Lindstrom J., Eriksson J.G., Valle T.T., et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial. J Am Soc Nephrol 14 Suppl 2 (2003) S108-S113
11. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
12. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368 (2006) 1096-1105
13. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
14. Chiasson J.-L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 290 (2003) 486-494
15. Pan C.-Y., Gao U., Chen J.-W., et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 61 (2003) 183-190
16. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care 27 (2004) 155-161
17. Walker E.A., Molitch M., Kramer M.K., et al. Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29 (2006) 1997-2002
18. Ratner R.E., and for the Diabetes Prevention Program Research Group. An update on the Diabetes Prevention Program. Endocr Pract 12 Suppl 1 (2006) 20-24
19. Xiang A.H., Peters R.K., Kjos S.L., et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55 (2006) 517-522
20. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134 (2001) 61-71
21. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 1304-1316
22. Hamman R.F., Wing R.R., Edelstein S.L., et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29 (2006) 2102-2107
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
25. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002) 2563-2569
26. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
27. NAVIGATOR data presented at American Heart Association's Scientific Sessions provide new insights about cardiovascular and diabetes risk (November 16, 2005). Available at: http://www.pharma.us.novartis.com/newsroom/pressReleases/releaseDetail.j sp?PRID=1885 Accessed July 16, 2007.
28. PRNewswire-First Call (February 17, 2004). Aventis S.A. announces five-year ORIGIN trial to investigate reduction in heart disease risk with Lantus® insulin. Available at: http://www.biospace.com/news_story.aspx?NewsEntityId=15175820 Accessed July 16, 2007.
29. Weber M.A. Hypertension treatment and implications of recent cardiovascular outcome trials. J Hypertens 24 Suppl 2 (2006) S37-S44